Zhou Guoying Comments | Oncolytic virus treatment of malignant brain tumor phase I clinical results are positive, more than 20 years of persistence finally sees the light

On April 12, at the 2021 American Association for Cancer Research (AACR) annual meeting, oncolytic virus therapy development company Treovir announced the clinical phase I of G207 in 12 patients with recurrent glioma (7-18 years old) Positive results of the study (NCT02457845).

In terms of survival impact, the median overall survival of patients with malignant glioma participating in the trial was 12.

Kaplan-Meier curve of overall survival rate of patients receiving G207 treatment

In terms of safety, there were no dose-limiting toxic effects or serious adverse events related to the administration of G207.

The results of immunohistochemical staining of CD8+ T cells in the tissues of 4 patients before and after treatment

Research breakthroughs

G207 is the earliest generation of herpes simplex oncolytic virus.

Brain tumor treatment challenges

In the clinical treatment of brain tumors, due to its insensitivity to radiotherapy and chemotherapy, coupled with the blood-brain barrier and other factors, the clinical treatment methods are very limited.

Yinuowei layout

Aiming at the characteristics of herpes simplex oncolytic virus, as a neurotropic virus, whose replication ability in nerve cells exceeds that of other somatic cells, Enova has further attenuated the company’s first product line MVR-T3011.

Future breakthrough direction

Looking forward to the next few years, I think that the field of oncolytic viruses may make breakthroughs in the following areas: First, oncolytic viruses will be used more in combination to revolutionize the efficacy of other anti-tumor drugs; secondly, The limitations of intratumoral administration will gradually be broken by intravenous oncolytic virus products; in addition, as more research and development results of immunotherapy appear, oncolytic viruses will also be armed with more effective immunotherapy gene combinations, making oncolytic viruses The single-drug efficacy of the drug has reached a new level.